Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$73.78 USD

73.78
283,441

+0.40 (0.55%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $73.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Cencora (COR) to Report Q1 Earnings: What's in the Cards?

Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Stryker's (SYK) fourth-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?

Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.

Reasons to Add Merit Medical (MMSI) to Your Portfolio Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update

Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth

Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.

Charles River's (CRL) New Launch to Boost Gene Therapy Programs

Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.

DexCom's (DXCM) G7 Links With Tandem's Insulin Pump in Europe

Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.

Masimo (MASI) Gains on Favorable Ruling in Apple Watch Dispute

Masimo (MASI) rides on the continuation of the import ban on certain models of Apple watches using disputed blood oxygen sensors.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.

ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.

Here's Why You Should Add McKesson (MCK) to Your Portfolio Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio Now

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.

Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.

Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View

Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.